• ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE

Recent announcements

Developing innovative drugs

ImmuPharma PLC is one of the leading specialist drug development companies listed on AIM of the LSE. Our corporate strategy and business model differentiates us from many of our peers.

We have UK, French and Swiss operations and have a formal research collaboration with Europe’s largest fundamental research organization in Europe, the Centre National de la Recherche Scientifique (CNRS). ImmuPharma has received to-date $45 million from a corporate deal with a US pharmaceutical company and a number of grants from French government organisations for three of our drug candidates. Our most advanced compound has recently been given the approval from the US FDA to enter phase III with a special protocol assessment and Fast Track designation.

With a partnership-based business model, a small core of full time staff, a low R&D costbase, a strong balance sheet and diversified compounds and pipeline, we believe we are a risk adverse and exciting pharma/biotech opportunity.

ImmuPharma PLC has an impressive list of shareholders/investors, both institutional as well as private clients that have supported the Company through its history and have helped finance product development.

Share Price

Market Cap

Nominated Adviser & Broker
Northland Capital Partners Ltd
www.northlandcp.co.uk

Public Relations & Investor Relations
lisa.baderoon@immupharma.com

Professional advisers

Auditors
Nexia Smith & Williamson Audit Limited,
London, U.K.

Bircham Dyson Bell LLP
London, U.K.
Badertscher Rechtsanwälte AG, Zurich, Switzerland

Patent Agents
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France

Manufacturers
Under contract with a leading manufacturer in the peptides field

“We ended 2016 by announcing a key milestone for
ImmuPharma with the completion, on track, of the
recruitment of the full 200 patients into our Pivotal Phase III
trial of Lupuzor™.”

Tim McCarthy, Chairman, ImmuPharma PLC

To contact us click here